Literature DB >> 10426476

Cannabinoid receptors undergo axonal flow in sensory nerves.

A G Hohmann1, M Herkenham.   

Abstract

Cannabinoids modulate nociceptive processing through central and peripheral mechanisms. The present study was conducted to evaluate axonal flow of cannabinoid receptors from the dorsal root ganglion to the periphery and to identify the putative involvement of CB1 and/or CB2 receptor subtypes. The sciatic nerve was tightly ligated to dam the flow of cannabinoid receptors to the periphery. The densities of cannabinoid receptors proximal and distal to one or two tightly constrictive ligatures was evaluated using in vitro receptor binding and high-resolution emulsion autoradiography. In both models, [3H]CP55,940 binding accumulated proximal as opposed to distal to the ligature. These data indicate that axonal transport of cannabinoid receptors to the periphery was occluded by tight constriction of the sciatic nerve. In situ hybridization histochemistry revealed that dorsal root ganglia cells synthesize CB1 but not CB2 receptor messenger RNA. By contrast, CB2 messenger RNA was highly expressed in sections of rat spleen that were processed together with the dorsal root ganglia, as previously described. These data demonstrate that neuronal cannabinoid CB1 receptors are synthesized in cells of the dorsal root ganglia and inserted on terminals in the periphery.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10426476     DOI: 10.1016/s0306-4522(99)00220-1

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  48 in total

Review 1.  Mechanism of cancer pain.

Authors:  Brian L Schmidt; Darryl T Hamamoto; Donald A Simone; George L Wilcox
Journal:  Mol Interv       Date:  2010-06

Review 2.  Inhibiting the breakdown of endogenous opioids and cannabinoids to alleviate pain.

Authors:  Bernard P Roques; Marie-Claude Fournié-Zaluski; Michel Wurm
Journal:  Nat Rev Drug Discov       Date:  2012-04       Impact factor: 84.694

Review 3.  CB2: a cannabinoid receptor with an identity crisis.

Authors:  Brady K Atwood; Ken Mackie
Journal:  Br J Pharmacol       Date:  2010-06       Impact factor: 8.739

4.  The antinociceptive effects of intraplantar injections of 2-arachidonoyl glycerol are mediated by cannabinoid CB2 receptors.

Authors:  J Guindon; J Desroches; P Beaulieu
Journal:  Br J Pharmacol       Date:  2006-12-18       Impact factor: 8.739

Review 5.  The endocannabinoid system and pain.

Authors:  Josée Guindon; Andrea G Hohmann
Journal:  CNS Neurol Disord Drug Targets       Date:  2009-12       Impact factor: 4.388

6.  Chronic blockade of cannabinoid CB2 receptors induces anxiolytic-like actions associated with alterations in GABA(A) receptors.

Authors:  María S García-Gutiérrez; Borja García-Bueno; Silvia Zoppi; Juan C Leza; Jorge Manzanares
Journal:  Br J Pharmacol       Date:  2012-02       Impact factor: 8.739

7.  Brain-Permeant and -Impermeant Inhibitors of Fatty Acid Amide Hydrolase Synergize with the Opioid Analgesic Morphine to Suppress Chemotherapy-Induced Neuropathic Nociception Without Enhancing Effects of Morphine on Gastrointestinal Transit.

Authors:  Richard A Slivicki; Shahin A Saberi; Vishakh Iyer; V Kiran Vemuri; Alexandros Makriyannis; Andrea G Hohmann
Journal:  J Pharmacol Exp Ther       Date:  2018-10-01       Impact factor: 4.030

8.  The neuronal distribution of cannabinoid receptor type 1 in the trigeminal ganglion of the rat.

Authors:  T J Price; G Helesic; D Parghi; K M Hargreaves; C M Flores
Journal:  Neuroscience       Date:  2003       Impact factor: 3.590

Review 9.  Targeting fatty acid amide hydrolase (FAAH) to treat pain and inflammation.

Authors:  Joel E Schlosburg; Steven G Kinsey; Aron H Lichtman
Journal:  AAPS J       Date:  2009-01-29       Impact factor: 4.009

Review 10.  Cannabinoid CB2 receptor-mediated anti-nociception in models of acute and chronic pain.

Authors:  Maulik D Jhaveri; Devi R Sagar; Steven J R Elmes; David A Kendall; Victoria Chapman
Journal:  Mol Neurobiol       Date:  2007-10-02       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.